Original Paper

Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1†

  1. Yukiko Shibahara1,
  2. Yasuhiro Miki1,
  3. Yoshiaki Onodera1,
  4. Shuko Hata1,
  5. Monica SM Chan1,2,3,4,
  6. Christopher CP Yiu1,3,
  7. Tjing Y Loo1,2,3,4,
  8. Yasuhiro Nakamura1,
  9. Jun-ichi Akahira1,
  10. Takanori Ishida5,
  11. Keiko Abe1,
  12. Hisashi Hirakawa6,
  13. Louis WC Chow2,3,4,7,
  14. Takashi Suzuki1,
  15. Noriaki Ouchi5,
  16. Hironobu Sasano1,*

Article first published online: 30 APR 2012

DOI: 10.1002/path.4019

Issue

The Journal of Pathology

The Journal of Pathology

Volume 227, Issue 3, pages 357–366, July 2012

Additional Information

How to Cite

Shibahara, Y., Miki, Y., Onodera, Y., Hata, S., Chan, M. S., Yiu, C. C., Loo, T. Y., Nakamura, Y., Akahira, J.-i., Ishida, T., Abe, K., Hirakawa, H., Chow, L. W., Suzuki, T., Ouchi, N. and Sasano, H. (2012), Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J. Pathol., 227: 357–366. doi: 10.1002/path.4019

Author Information

  1. 1

    Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

  2. 2

    UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, 10/F, Luk Kwok Centre, 72 Gloucester Road, Wanchai, Hong Kong

  3. 3

    Department of Surgery, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

  4. 4

    Clinical Trial Centre, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong

  5. 5

    Department of Surgery, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

  6. 6

    Department of Surgery, Tohoku Kosai Hospital, 2-3-11 Kokubun-cho, Aoba-ku, Sendai, Miyagi 980-0803, Japan

  7. 7

    Organisation of Oncology and Translational Research, Unit A, 9/F, CNT Commercial Building, 302 Queen's Road Central, Hong Kong

*Department of Pathology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan.

  1. †

    Conflict of interest statement: HS received educational research grants from Novartis Japan Oncology and Pfizer Japan Oncology. YM received educational research grants from Pfizer Japan. The other authors disclosed no potential conflicts of interest.

Publication History

  1. Issue published online: 6 JUN 2012
  2. Article first published online: 30 APR 2012
  3. Accepted manuscript online: 9 MAR 2012 10:02AM EST
  4. Manuscript Accepted: 21 FEB 2012
  5. Manuscript Revised: 7 FEB 2012
  6. Manuscript Received: 24 OCT 2011

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (2468K)
FilenameFormatSizeDescription
path_4019_sm_suppinfofs1.tif57KSupporting Information: Figure S1. Ki-67 proliferation index (%) of pre-AI and post-AI treatment in the patients.
path_4019_sm_suppinfo.doc22KSupporting Information: Legend to Figure S1

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

View Full Article with Supporting Information (HTML) Get PDF (2468K)